Abstract Etidronate is one of the best known bisphosphonates (BP) derivatives. It is often used as a reference drug in research related to hypercalcaemia and other common bone diseases. 2,3,3-trisphosphonate (TrisPP) is brand new analogue of BP, that also contains a 'germinal bisphosphonate' unit with an additional phosphoryl group attached in proximity to the BP unit. It is known that BPs bind to calcium by chemisorptions to form Ca-BP complexes through (O)P-C-P(O) moiety and hydrogen coordinations, and so they suppress calcium flow by interfering with Ca 2? channel operations. The mechanistic actions of BP, involving interactions and regulations of Ca 2? , are somewhat similar to the pathogenesis of well-known neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. To investigate if neuroprotective effects are exhibited by the compounds of interests, we used a rat adrenal pheochromocytoma cell line (PC12) as our in vitro model to observe any occurrence of neuron inter-reflection. We pre-treated these PC12 cells with etidronate and TrisPP before challenging the cells with a high concentration of the neurotoxin, glutamate. Our data showed that pretreatment with 100 lM etidronate partially ameliorated the glutamate-induced decrease in cell viability (47 %), whereas pre-treating cells with 10-100 lM TrisPP showed remarkable cell protection (78-86 %). Moreover, pretreatments of the cells with etidronate or TrisPP attenuated cell apoptosis, reactive oxygen species generation, Ca 2?
Introduction
Bisphosphonates (BP) are a category of drugs used to treat various bone diseases, such as osteoporosis, Paget's disease, bone malignancy and other skeletal complications involving excessive bone loss. BP is often used in drug modelling studies to study interactions involving calcium and calcium metabolism [1] . All BP drugs share a common P-C-P functional unit in their chemical structures, which is called the 'geminal bisphosphonate' unit [2, 3] . Etidronate is first generation of BP used to treat osteoporosis. It has the simplest chemical structure (Fig. 1a ) of all BPs and it is often used as a reference in potency studies of other BP analogues [4] . BPs process similar biological functions as pyrophosphate, and have similar inhibitory effects on calcium phosphate formation and dissolution via the calcium homeostasis pathway. In vivo, BPs are potent inhibitors of soft tissue calcification, where they inhibit accretion of mineral into bone and resorption of bone. Therefore, in clinical practice, BPs are used to inhibit bone destruction, which leads to an increase in bone mineral density by suppressing bone resorption and the bone turn over process [5, 6] . Etidronate has three active binding sites, which allow ionic coordination to occur between Ca 2? in the hydroxyapatite and any of the oxygen atoms bonded to the BP or the acarbon moiety [2] . The trisphosphonate (TrisPP) we present in this work belongs to a brand new family of phosphonates, which were synthesised in situ by Cheong et al. [7] . This novel TrisPP is comprised of a 'geminal bisphosphonate' unit, with an additional phosphoryl group attached in proximity to the BP unit (Fig. 1b) . The additional binding site present in the TrisPP is expected to display a better intercellular Ca 2? binding affinity in our neuronal cell line. As a consequence, the intra-cellular influx will be reduced and the overall intracellular Ca 2? concentration will be suppressed or even inhibited. Herein, is the first report documenting in vitro studies of the neuroprotective effects of the novel 2,3,3-TrisPP.
Neurodegenerative disorders and osteoporosis are two common, chronically progressive, degenerative diseases, that share some common risk factors such as advanced age [8] . It is worth noting that patients who suffer from osteoporosis are more often also diagnosed with neurodegenerative complications. On the other hand, patients with Parkinson's disease are found to have lower bone mineral densities when compared with age-matched controls [9] [10] [11] . Recent studies showed patients with osteoporosis who underwent BP therapy have a lower risk of dementia [12] [13] [14] . Moreover, recent research also found that the Alzheimer's disease risk genes such as Ab42 and APP are also risk factors for osteoporosis [15, 16] . There is strong evidence suggesting links may exist inherently between neurodegenerative disorders and bone loss. There are obvious reasons to believe that neurodegenerative disorders are associated with osteoporosis (and other bone diseases) [13] and that they may share a common pathogenesis.
It is known that neuronal cell apoptosis is caused by excessive intracellular calcium influx due to an over excitation of glutamate receptors (i.e. NMDA) and nonspecific ion-channel opening triggered by glutamate binding. A molecular interaction study reported by Lane et al. [17] found mitochondrial dysfunction caused aberrant reactive oxygen species (ROS) generation and Ca 2? deregulation, which explain a conserved mechanism involved in neurodegenerative disorders and osteoporosis pathological alterations. Our previous studies concerning neurotoxicity effects [18] have provided adequate evidence to show the increase of oxidative stress was directly related to the excessive intracellular accumulations of ROS and Ca 2? , which led to apoptosis of differentiated PC12 cells [19, 20] . Overloading oxidative stress is certainly a key factor for PC12 cell apoptosis, the underlying intracellular mechanisms involved in such a process can be studied via ROS generation and SOD activities [21] . It is worthwhile to consider these important factors and to extend the evaluation of BPs and their derivatives to explore their effect on reactive oxygen species (ROS) generation and Ca 2? concentration. Similarly, it is important to monitor any occurrence of reversible neurodegenerative effects on neurons that were damaged by glutamate [22] or whether these compounds may have a protective role. These in vitro assays would allow better understanding of the possible pathogenesis shared among neurodegeneration and bone diseases, with an aim to expand the pharmacological potential of clinical and novel BPs.
Materials and Methods

Chemicals and Reagents
Glutamate (purity [98 %) was purchased from Sigma (St. Louis, MO, USA). Etidronate (Sigma-Aldrich UK, etidronic acid [95 %) and 2,3,3-TrisPP (synthesised in situ) samples were acquired from the University of Hertfordshire, Hatfield, UK. RPMI 1640 cell culture medium, trypsin-EDTA and foetal bovine serum (FBS) were supplied by Gibco (Grand Island, NY, USA). Dimethyl sulfoxide (DMSO) and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) were purchased from Sigma Chemicals. Hoechst 33258, superoxide dismutase (SOD) and ROS test kits were purchased from Beyotime Institute of Biotechnology (Shanghai, China). The Annexin V-FITC propidium iodide (PI) apoptosis detection kit was obtained from Tianjin Sungene Biotech Co. Ltd (Tianjin, China). The rat caspase-3 ELISA kit was supplied by Shanghai Lengton Bioscience Co. Ltd (Shanghai, China).
Cell Culture and Sample Preparation
PC12 rat pheochromocytoma cells, which were obtained from the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, were cultured in RPMI 1640 medium (pH 7.4) supplemented with 10 % FBS and 1 % antibiotics (penicillin-streptomycin). Cells were grown in an incubator at 37°C in 95 % humidified air with (5, 10, 15, 20, 25, 30 mM) . These samples were incubated for 24, 48 and 72 h. The subsequent viability tests were carried out by pre-treating PC12 cells with different concentrations of etidronate or TrisPP (0.1, 1, 10, 100 lM) for 4 or 8 h, and the resulting cultures were washed with RPMI 1640 and then incubated in 25 mM glutamate for 24 h. Finally 10 lL MTT (0.5 mg/mL) indicator was added to each well and incubated for a further 4 h at 37°C. Excess MTT was removed and the insoluble dark blue formazan crystal was dissolved in 150 lL DMSO. The absorbance of formazan was measured using a microplate reader at wavelength 578 nm. The cell viability was calculated as a percentage against the control group [23] .
Cell Apoptosis Detection by Flow Cytometry
The apoptotic index of PC12 cells was determined using a FITC-Annexin V/propidium iodide (PI) apoptosis assay kit, and analysed by flow cytometry [24] . The PC12 cells were plated in 6-well plates and exposed to 100 lM etidronate or TrisPP for 8 h. The resulting cells were washed and treated with 25 mM glutamate for 24 h. The cells were then harvested, washed twice with cold phosphate-buffered saline (PBS, pH 7.4) and finally suspended in a binding buffer containing 5 lL V-FITC and 10 lL PI at room temperature in a dark environment for 15 min before being examined by a flow cytometer (Beckman-Coulter, USA). The percentage of cell apoptosis was obtained as follows:
%Cell apoptosis ¼ Level of assigned group=Level of control group ð Þ Â 100
Nuclear morphology: Hoechst 33258
Hoechst 33258 staining was used to evaluate morphological changes in all cell groups [25] . The PC12 cells were seeded in 96-well plates and were exposed to 100 lM etidronate or TrisPP for 8 h. The resulting cells were washed and treated with 25 mM glutamate for 24 h, then. 100 lL Hoechst 33258 was added to each well and the cells were incubated for 30 min at 37°C in a dark environment. Each sample was washed twice with PBS and the Hoechst stained nuclei were visualised using a fluorescence microscope.
Measurement of ROS Generation
The level of ROS was measured using the dichlorodihydrofluorescein diacetate (DCFH-DA) fluorescent probe [26] . PC12 cells were seeded in 6-well plates, which were then treated with 100 lM etidronate or TrisPP for 8 h. All cells were then washed and exposed to 25 mM glutamate for 24 h. Cells were incubated with the final concentration of 10 mM DCFH-DA and kept in the dark for 30 min at 37°C. The methodology and procedures were followed as described in the ROS assay kit. The samples were then washed twice with PBS and the DCFH fluorescence intensities were detected by flow cytometry.
Measurement of SOD Enzyme Activity
The level of SOD activity was measured using a SOD kit. The PC12 cells were plated in 6-well plates and exposed to 100 lM etidronate or TrisPP for 8 h, followed by treatment with 25 mM glutamate for 24 h. The resulting PC12 cells were homogenized with PBS and lysed with lysis buffer for 30 min at 4°C. The lysates were centrifuged at 12,000 rpm for 15 min. Then, the supernatant obtained was used for the determination of SOD enzyme activity according to the kit manufacturer's instructions. The absorbance was measured at 450 nm using a microplate reader.
Measurement of Intracellular Ca 21
Intracellular calcium concentration was determined using Fluo-3/AM fluorescent dye. The PC12 cells were plated in 6-well plates and exposed to 100 lM etidronate or TrisPP for 8 h, followed by treatment with 25 mM glutamate for 24 h. Afterward, the cells were washed twice with cold PBS and incubated with a final concentration of 5 lM Fluo-3/AM for 30 min in the dark at 37°C. The fluorescence intensity of Ca 2? was examined by confocal laser scanning microscopy (Olympus, Japan) at an excitation wavelength of 488 nm and an emission wavelength of 525 nm. Data analysis and image processing were conducted using image J software.
ELISA to Detect the Expression of Caspase-3
Samples were prepared identically to the method described for the SOD assay. The expression of caspase-3 was detected by a rat caspase-3 ELISA kit. The specific experimental method provided by the manufacturer was followed. The absorbance was measured at 492 nm using a microplate reader.
Statistical Analysis
All of the results were expressed as mean ± standard deviation (SD) for three separate experiments, which were analyzed by SPSS 16.0 and Graph Pad Prism 5. The statistical significance of the changes between tested groups and the control group were analyzed by ANOVA followed by Dunnett's multiple comparison test. And value of P \ 0.05 was considered significant.
Results
Cell viability was determined by the MTT assay, selected concentrations of etidronate, TrisPP and glutamate were used to perform these tests. Standardized tests were carried out by exposing PC12 cells to different concentrations (5, 10, 15, 20, 25, 30 shows the percentage of viable PC12 cells pre-treated with 0.1, 1, 10 and 100 lM of etidronate for 4 or 8 h. Our data indicates that the 100 lM concentration of etidronate provided optimal cell recovery over 4 and 8 h (42.98 and 47.44 %). This study was repeated using different concentrations of TrisPP (0.1, 1, 10 and 100 lM). Interestingly, the pre-treatment with TrisPP showed a more significant cell recovery (Fig. 2c) (Fig. 2d ). This treatment concentration (100 lM) and condition (8 h) were therefore used in our subsequent in vitro experiments for intra-cellular mechanistic examinations. Cell apoptosis testing was performed using FITC-Annexin V/propidium iodide (PI) and the apoptotic rate was monitored by flow cytometry. As shown in Fig. 3a , the apoptotic rate was remarkably increased when PC12 cells were treated with the glutamate standard (178 %) as compared with the control group (100 %). A lower apoptosis rate was observed when PC12 cells were pre-treated with 100 lM etidronate (145 %) and TrisPP (137 %). The results indicated that both etidronate and TrisPP can be used to prevent or/reduce apoptosis in glutamate-injured PC12 cells. The expression of caspase-3 is commonly used for examining the apoptosis index, therefore in our study, the level of caspase-3 was determined and the results were used to support the neuroprotective effects induced by the presence of etidronate and TrisPP. In Fig. 3b , glutamateinjured cells showed a high level of caspase-3 expression (1.5 ng/mL), but pre-treatment with 100 lM etidronate (1.1 ng/mL) and TrisPP (0.9 ng/mL) kept the level of caspase-3 expression close to that observed in the control group (0.8 ng/mL).
The cell nuclei morphology was analyzed by Hoechest 33258 staining and visualization under a fluorescent microscope. Fluorescent images in Fig. 4a-d show all PC12 cells underwent nuclear condensation, nuclear segmentation and appeared in their apoptotic form after treatment with glutamate standard alone or in the present of etidronate or TrisPP. Although all of which, the glutamate treated cells represented a typical process of cell apoptosis, a more alleviated cell nuclei damages were observed when cells were pre-treated with 100 lM etidronate (Fig. 4c) and TrisPP (Fig. 4d ) for 8 h.
ROS levels were determined using the DCFH-DA reagent and measured using flow cytometry. SOD activities were examined using a commercial SOD kit and measuring the absorbance with a reader. As shown in Fig. 5 , the level of ROS had significantly increased to 88 % when cells were treated with 25 mM glutamate standard compared with the control group (56.8 %). Whereas, when glutamate-injured cells had been pre-treated with 100 lM etidronate or TrisPP for 8 h, their ROS generation was significantly reduced to 77.43 and 66.60 %, respectively.
In contrast, as indicated in Fig. 6 , cells pre-treated with etidronate and TrisPP were found to have their SOD # P \ 0.05 versus control group; * P \ 0.05, ** P \ 0.01 versus group exposed to glutamate alone activities recovered to 12 U/mg protein and 14 U/mg protein from the low SOD activity induced by glutamate (16 U/mg protein).
Intracellular Ca 2? concentration were examined using Fluo-3/AM fluorescent dye and the resulting emission data was acquired using a confocal laser microscope (Ex. 488 nm; Em. 525 nm). The high fluorescent intensity observed in Fig. 7e shows the intracellular Ca 2? concentration was significantly elevated by treatment with glutamate when compared with the control group, as shown in Fig. 7a, b . Whereas pre-treating glutamate-injured cells with 100 lM etidronate reduced the glutamate-induced increase in intracellular Ca 2? concentration (Fig. 7c) . TrisPP (Fig. 7d) almost completely prevented the glutamate-induced increase in intracellular Ca 2? concentration.
Discussion
Neurodegenerative disorders are progressive multi-factorial autoimmune disorders, this group of diseases is normally characterized by injury and apoptosis of neurons. Glutamate excitotoxicity is well-known factor that triggers cell death in many central nervous system disorders. Several clinical glutamate antagonists such as simvastatin and estrogen (17b Estradiol) are prescribed to patients to promote neuroprotective effects [27] . Although BPs work as anti-resorptive drugs and are the best known treatments for Paget's disease, osteoporosis, hypercalcaemia and other bone diseases [1] [2] [3] [4] 28] , a number of articles have been published in regard to using BPs as alternative treatments for anti-parasitic [29] , anti-infective [30] and anti-cancer therapies [31] [32] [33] [34] . It has been recognized recently that BPs inhibit osteoclast activity through common mechanistic pathways to manipulate isoprenoid and cholesterol biosynthesis [35] . As mentioned earlier, there is strong evidence showing links and associations between neurodegenerative and bone disorders [13] . To initiate our exploration in this area, as well as to understand the underlying bio-mechanisms, we performed a series of in vitro assays to study the neuroprotective effects of 'etidronate' and '2,3,3-TrisPP'. Etidronate is conventional BP analogue that we used as a reference in our study, while 2,3,3-TrisPP is a novel analogue of BP. With regard to the structure activity relationship (SAR) of 2,3,3-TrsiPP, it has a rather small molecular size when comparing to other Fig. 4 The nuclear morphology of apoptotic cells imaged by a fluorescence microscope (9200). # P \ 0.05, ## P \ 0.01 versus control group; * P \ 0.05, ** P \ 0.01 versus group exposed to glutamate alone glutamate antagonists, which is essential for crossing the blood brain barrier (BBB). It is believed that removing the -OH group from the general BP molecule reduces its bonebinding ability and the presence of a more lipophilic substituent enhances cell or tissue penetration [35] . Therefore, the presence of the COOH group with an additional phosphoryl unit of TrisPP implies a practical application as a neuroprotective agent while retaining the anti-resorptive function for bone loss complications.
Extracellular glutamate binds to N-methyl-D-aspartate (NMDA) receptors in a calcium channel membrane, where it mediates transport of positive ions (i.e. Ca 2? ). A high intracellular calcium concentration is an indication of excessive accumulation of glutamate; hence glutamate may act as a neurotoxin, which may lead to learning disability and memory loss [36, 37] . Mechanistic studies have proved that neuronal death induced by glutamate is often caused by excessive ROS production and Ca 2? influx [38, 39] . PC12 cells, a rat pheochromocytoma cell line; that possesses neuron-like characteristics, have been widely used as an in vitro model system for neuronal damage studies [40] . Thus, we expect a thorough examination of the effects of etidronate and TrisPP on ROS level and Ca 2? influx in glutamate-induced neurotoxicity in PC12 cells will provide crucial information for the exploration of these potentially neuroprotective medications.
To examine the neuroprotective effects of the compounds of interest, we pre-treated PC12 cells using different concentrations (0.1, 1, 10 and 100 lM) of etidronate and TrisPP for 4 and 8 h prior to challenging the cells using the optimal neurotoxic concentration (25 mM) of glutamate-selected from our initial cell viability assay (Fig. 2a) . As shown in Fig. 2b , our cell viability data demonstrated that PC12 cells reached an optimum recovery of 47.4 % when they were pre-treated with 100 lM of etidronate for 8 h. Astonishing results were observed in cultures pretreated with lower concentrations of TrisPP (10 and 100 lM) for 4 and 8 h: cell recovery reached 66-86 % (Fig. 2c) . Although TrisPP promoted an excellent recovery rate and seemed to exert a much higher protective effect on the glutamate-injured PC12 cells than etidronate did, the data obtained in the apoptosis assay (Fig. 3a, b) of the two were indeed comparable. The apoptosis rates fell to 145-137 % when PC12 cells were pre-treated with 100 lM of etidronate and TrisPP for 8 h, still significantly lower than glutamate treated cells (178 %). Evaluations of caspase-3 expression showed that pre-treatment with etidronate and TrisPP significantly down-regulated caspase-3 expression against apoptosis, as expected. This observation was in agreement with the result of the apoptosis assay above. Morphological images of nuclei obtained from Hoechst 33258 staining show PC12 cells were severely damaged via nuclei condensation (Fig. 4b) . In contrast, only very mild nuclei damage was observed if PC12 cells were pre-treated with etidronate or TrisPP. Although both etidronate and TrisPP appeared to exhibit anti-apoptotic ability in the injured PC12 cells, a stronger protective effect again was observed from the pre-treatment with TrisPP.
In order to understand the mechanisms of the neuroprotective effect exhibited by etidronate and TrisPP, we acquired further in vitro intracellular measurements to quantify the levels of ROS, SOD activity, Ca 2? influx and caspase-3 expression in glutamate-challenged PC12 cells.
It is known that neurodegenerative disorders such as AD and PD are associated with neuronal apoptosis, which is closely related to increased ROS and intracellular Ca 2? production [41, 42] . Excessive accumulation of intracellular Ca 2? was an important signal of apoptosis and ROS generation [43, 44] . SOD is an important antioxidant, which denotes antioxidant capacity of cells and regulates the level of ROS [21] . Our experiments indicated that pretreatments with etidronate and TrisPP prevented cell apoptosis induced by glutamate via an inhibition of ROS generation (Fig. 5a-e) and stimulation of SOD activity (Fig. 6 ). These observed results were clearly associated with the intracellular Ca 2? influx being suppressed by the pre-treatments with etidronate and TrisPP (Fig. 7a-e) , which overall reduced the apoptotic rate. Based on an analysis of these data as a whole, we propose that these BP analogues exhibit neuroprotective effects by attenuating the apoptotic process through interaction with calcium to ameliorate the intra-cellular Ca 2? overload and # P \ 0.05 versus control group; * P \ 0.05, ** P \ 0.01 versus group exposed to glutamate alone. Scale bar is 50 lm results acquired from TrisPP pre-treatments were very similar to data generated by the control group. This has convinced us to further explore this novel compound and perhaps open up a fruitful area of drug discovery for the treatment of autoimmune diseases.
Conclusion
Our research has confirmed that both etidronate and TrisPP provide excellent neuroprotective effects in PC12 cells against glutamate-induced apoptosis. Our in vitro results indicate that TrisPP far exceeds the protective effects of etidronate in the concentration range of 0.1-100 lM. Preliminary mechanistic studies suggested that both etidronate and TrisPP convey neuroprotective effects through attenuating ROS generation, stimulating SOD activity, suppressing Ca 2? influx and down-regulating caspase-3 expression (Fig. 8) . With all the results collected, we are convinced that etidronate, especially TrisPP and perhaps other BP analogues, can be used as alternative medicines for patients suffering from neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases. We also strongly believe that our study has introduced the concept of applying a single treatment to simultaneously target dual complications caused by neuronal and bone degeneration.
Further explorations will focus on in vivo assays using brain slices and animal models to carry out a more comprehensive study on the neuroprotective effects promoted by 2,3,3-TrisPP and other BP analogues. 
